Charles Schwab’s BioAge Labs BIOA Stock Holding History
Bought
Maintained
Sold
Other funds holding BIOA
Charles Schwab's BIOA Position: Q3 2026 in Review
Charles Schwab increased its BioAge Labs (BIOA) stake by 16% in Q3 2026, buying an estimated $608K and bringing the position to 317,258 shares worth $2.25M. The position accounts for ﹤0.01% of the portfolio, ranked #2749.
Charles Schwab first reported a position in BIOA in Q4 2024 and has held it in 8 quarters since. The position peaked at $6.7M in Q2 2026. 162 funds tracked by Wall St. Rank hold BIOA as of Q3 2026.
- Charles Schwab held 317,258 shares of BioAge Labs worth $2.25M as of Q3 2026.
- Charles Schwab bought 43,887 BioAge Labs shares in Q3 2026, an estimated $608K.
- BioAge Labs made up ﹤0.01% of Charles Schwab's portfolio in Q3 2026, its #2749 holding.
- Charles Schwab first reported a position in BioAge Labs in Q4 2024 and has held it in 8 quarters since.
- Charles Schwab's BioAge Labs position peaked at $6.7M in Q2 2026.
- 162 funds tracked by Wall St. Rank held BioAge Labs as of Q3 2026.
Based on Charles Schwab's 13F filing for Q3 2026, filed 16 Nov 2026.